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Abstract:  
 
Objective: Guidelines for assessment of non-alcoholic fatty liver disease 
(NAFLD) have been published in 2016 by NICE and EASL-EASD-EASO. 
Prior to publication of these guidelines we performed a cross-sectional survey 
of Gastroenterologists and Hepatologists regarding NAFLD diagnosis and 
management.  
 
Design: An on-line survey was circulated to members of BASL and BSG 
between February-May 2016. 
 
Results: 175 Gastroenterologists / Hepatologists responded, 116 completing 
the survey, representing 84 UK centres. 22% had local NAFLD guidelines. 
45% received >300 referrals per-year from primary care for investigation of 
abnormal liver function tests (LFTs).  
Clinical assessment tended to be performed in secondary rather than primary 
care including BMI (82% vs 26%) and non-invasive liver screen (86% vs 32%) 
and ultrasound (81% vs 37%).  
Widely used tools for non-invasive fibrosis risk-stratification were AST/ALT 
ratio (53%), Fibroscan® (50%), and NAFLD-Fibrosis score (41%). 78% 
considered liver biopsy in selected cases. 
50% recommended 10% weight-loss target as first-line treatment. Delivery of 
lifestyle interventions was mostly handed back to primary care (56%). A 
minority have direct access to community weight-management services 
(22%).  
Follow-up was favoured by F3/4 fibrosis (72.9%), and high-risk non-invasive 
fibrosis tests (51%). Discharge was favoured by simple steatosis at biopsy 
(30%), and low-risk non-invasive scores (25%).  
 
Conclusions: The survey highlights areas for improvement of service 
provision for NAFLD assessment including improved recognition of NASH in 
people with type-2 diabetes, streamlining abnormal LFTs referral pathways, 
defining non-invasive liver fibrosis assessment tools, use of liver biopsy, 
managing metabolic syndrome features, and improved access to lifestyle 
interventions.  
 
Summary ‘box’ 
What is already known 
about this subject? 
 
New clinical guidelines for NAFLD 
assessment, diagnosis and 
treatment were published in 2016 
from NICE and EASL 
What are the new 
findings? 
 
This national cross sectional survey 
captured opinion on the state of 
NAFLD assessment in the UK, 
before guideline publication 
How might it impact on 
clinical practice in the 
foreseeable future? 
The survey has identified priority 
areas for service improvement and 
implementation of recent guidelines 
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INTRODUCTION 
 
NAFLD is highly prevalent, affecting ~25% of the population and is likely to 
increase further due to the obesity epidemic 1. NAFLD occurs due to 
accumulation of liver fat (steatosis) in the context of obesity and insulin 
resistance leading to generation of lipotoxic intermediates, and a cycle of liver 
cell stress, inflammation and fibrosis. This can progress ultimately to 
decompensated cirrhosis and/or hepatocellular carcinoma (HCC) 2.  
NAFLD is typically asymptomatic and therefore the majority of patients remain 
undiagnosed. However, other associated features of metabolic syndrome 
including obesity, insulin resistance, type 2 diabetes, hyperlipidaemia and 
hypertension may frequently come to medical attention, and also affect 
prognosis, increasing risk of cardiovascular mortality in this group of patients 
3. Thus the typical patient with NAFLD crosses many of the boundaries 
between primary and secondary care and between traditional clinical 
specialities.  
 
The first line intervention to treat NAFLD is lifestyle changes to lose weight, 
although many patients with NAFLD find support for lifestyle interventions 
difficult to access or achieve 4.  
 
Although there are currently no licensed drug therapies to treat NASH, several 
agents are in phase 2 and 3 clinical trials. Therefore, the major priorities of 
healthcare providers at present are to identify those at risk of NAFLD, 
establish a definite diagnosis, initiate lifestyle interventions, identify those with 
advanced disease for HCC surveillance, and identify those with earlier fibrosis 
but potentially progressive NASH who may benefit from new treatments in the 
future. 
 
In 2016 two clinical guidelines for the assessment and treatment of non-
alcoholic fatty liver disease (NAFLD) have been published; NICE clinical 
guideline 49 5 and the joint European Associations for the study of the Liver 
(EASL), European Association for the study of Diabetes (EASD) and the 
European Association for the study of Obesity (EASO) 6. The publication of 
both these guidelines represents an important landmark in NAFLD clinical 
practice and research. It also highlights the many challenges and 
uncertainties in the existing evidence base posed by this important clinical 
problem.  
 
The aim of the present survey was to understand the degree to which practice 
varies across the UK in identifying patients with NAFLD, diagnosis, risk 
stratification and treatment. Additionally, this data provides a context for the 
subsequent recommendations of NICE and EASL-EASD-EASO guidelines for 
assessment and treatment of NAFLD.  We have utilised the survey findings to 
recommend an ‘action plan’ to improve NAFLD management. 
 
METHOD 
Survey questions were agreed by the UK-NAFLD group. A 10 question on-line 
survey was circulated to members of the British Association for the Study of 
the Liver (BASL) (859 members) and British Society of Gastroenterology 
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(BSG) Liver Section (561 members) between February 2016 and May 2016. 
This was prior to the publication of NICE guideline 49 and contemporary to 
the EASL-EASD-EASO guideline release. The full list of questions included in 
the survey is provided online supplemental appendix. 
 
Results: 
 
Respondents Sample of opinion. 175 gastroenterologist / hepatologists 
responded to the survey. 116 respondents provided complete responses, and 
there were 59 incomplete questionnaires. 84 separate NHS organisations 
across England, Scotland, Wales and Northern Ireland responded (Appendix). 
30 (17%) considered themselves district general hospital (DGH) 
Gastroenterologists, 50 (29%) were DGH Gastroenterologists with a 
hepatology interest, 67 (38%) were Hepatologists in a specialist liver unit, and 
28 (16%) in a liver transplant centre. There was no significant variance in 
completion rates by type of centre (table 1). 
 
38/175 respondents (22%) stated that their centre had local guidelines for 
NAFLD management. All the respondents that stated they had local NAFLD 
guidelines completed the survey. More respondents from specialist 
hepatology units (34%) and liver transplant centres (35%) stated they had 
local NAFLD guidelines than those in DGH gastroenterology (3%) or DGH 
with hepatology interest (8%) (table 1). 
  
NAFLD Assessment. 
The majority of new diagnoses of NAFLD are made following investigation of 
abnormal liver function tests (LFTs), that have typically been performed in 
primary care for some indication other than suspected NAFLD 7. The UK 
NAFLD survey data indicates a high demand for secondary care services to 
investigate abnormal LFTs with 49/110 (45%) of respondents reporting >300 
referrals per year from primary care for investigation of abnormal LFTs.   
 
Referrals from diabetes / metabolic services for investigation of abnormal 
LFTs are fewer than from primary care, with 63/99 (64%) of respondents 
reporting <50 referrals per year from these services. This supports the 
perception that NAFLD is under recognised in this high-risk population with 
type-2 diabetes (figure 1).  
 
A positive diagnosis of NAFLD is made on the basis of imaging evidence of 
hepatic steatosis, and exclusion of other causes of liver disease including 
alcohol related liver disease, viral hepatitis, autoimmune liver disease and 
haemochromatosis. NAFLD diagnosis therefore requires an initial clinical 
assessment for features of the metabolic syndrome, an alcohol history and a 
negative ‘non-invasive liver screen’ and abdominal ultrasound scan 8. The UK 
NAFLD survey questions sought to understand where in the diagnostic 
pathway an assessment for BMI, alcohol consumption and waist 
circumference are being made. BMI (82.6%) and alcohol history (79.1%) are 
usually performed in secondary care rather than in primary care, but waist 
circumference is not routinely performed in most units (56.5%) (Supplemental 
figure 1A). For diagnosis of NAFLD, the Fatty Liver Index (FLI) score, (an 
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algorithm based on BMI, waist circumference, GGT and fasting Triglycerides) 
is not routinely performed in 89.3% of respondents, although had been 
suggested by NICE as useful for NAFLD diagnosis. 
 
The survey data indicates that the non-invasive liver screen including ferritin 
(87.7%), hepatitis B and C serology (86%), liver auto-antibodies (91.2%), 
immunoglobulins (91.2%) and liver ultrasound (80.9%) are performed in the 
majority of cases by secondary rather than primary care (Supplemental figure 
1B). 
 
Assessment of Liver Fibrosis 
Various scoring systems/tools are available for the non-invasive assessment 
of liver fibrosis. Many require measurement of the AST, whereas others 
include transient elastography (fibroscan®) and serum fibrosis tests including 
serum Enhanced Liver Fibrosis (ELF) test. NICE recommends offering testing 
for advanced liver fibrosis to people with NAFLD using the ELF test5. 
The UK NAFLD survey attempted to capture data on which tools are currently 
most widely used for non-invasive fibrosis assessment (figure 2). The survey 
found that the AST is routinely performed by the hospital team in 71.4% of 
cases, and in 33.9% of primary care cases. The survey indicates that primary 
care do not routinely perform any assessment of liver fibrosis, with only 7.9% 
routinely performing AST/ALT ratio in primary care. The tools most commonly 
used routinely in secondary care are: AST/ALT ratio (53%), Transient 
Elastography (Fibroscan®) (50%), NAFLD Fibrosis score (41%), FIB-4 score 
(16%), APRI score (6%) and ELF test or other serum fibrosis markers (5%). 
There was variation in modalities used for liver fibrosis assessment according 
to type of centre, notably Fibroscan more likely to be performed in Specialist 
hepatology centres (71%) and transplant units (67%), than DGH 
gastroenterology (16%) or DGH hepatology interest (32%) centres (table 1). 
 
Liver Biopsy. 
Liver biopsy is an important tool for NAFLD assessment to establish a 
diagnosis of NASH by histological features of steatosis, hepatocyte ballooning 
and inflammation, and to stage degree of liver fibrosis. Neither the NICE nor  
EASL-EASD-EASO guidelines make specific recommendations regarding 
when to use liver biopsy in NAFLD assessment, although the EASL-EASD-
EASO guidance advocates the approach of applying non-invasive methods 
first, to avoid biopsy in low risk cases 6. In the UK NAFLD survey, 78% of 
respondents said they would consider liver biopsy in selected cases. The 
strength of agreement with a series of statements regarding use of liver 
biopsy in NAFLD was asked to attempt to understand the boundaries and 
indications for liver biopsy. The hierarchy of factors for which respondents 
agreed or strongly agreed with is shown in figure 3. There was general 
agreement that liver biopsy is indicated when an alternative diagnosis is in the 
differential, and/or where there are high non-invasive scores of fibrosis. There 
was also general disagreement that liver biopsy is poorly tolerated by 
patients. There does not appear to be a consensus of views regarding the 
utility of liver biopsy in those with escalating features of the metabolic 
syndrome and in those with intermediate non-invasive risk scores. 
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Extrahepatic conditions 
Extraheptic conditions are relevant to holistic care in NAFLD patients. NICE 
guidance highlights awareness that NAFLD is a risk factor for type 2 diabetes, 
hypertension and chronic kidney disease. Furthermore, there should be 
awareness that in people with Type 2 diabetes, NAFLD is a risk factor for 
atrial fibrillation, myocardial infarction, ischaemic stroke and death from 
cardiovascular causes 5. The survey sought to understand who manages 
features of the metabolic syndrome in patients with NAFLD. The survey data 
indicate that only in a minority does secondary care take ownership of these 
extra-hepatic conditions, the majority either providing advice to GP, or leaving 
extrahepatic conditions entirely for the GP to manage (Supplmental figure 2).  
 
Alcohol 
NICE guidelines state that people with NAFLD should stay within the national 
recommended limits for alcohol consumption. Most respondents of the survey 
are providing advice consistent with this, advising on both <14 units per week 
in those without advanced fibrosis (70.6%) and the calorific nature of alcohol 
(63%) should be moderated to help lose weight.  
 
Lifestyle modification 
Currently, lifestyle intervention to lose weight by diet and exercise is the first 
line treatment for NAFLD 9. The survey sought to identify whether services 
can provide access to effective lifestyle interventions. The majority of 
respondents relied on referral by GP to community weight management 
services (56.3%) to facilitate delivery of lifestyle interventions. A minority of 
respondents in secondary care had direct access to either a multidisciplinary 
clinic with dieticians and physiotherapists (20.9%) input, or tier 2 (26%), tier 3 
(23%) and / or tier 4 (26%) community weight management services. The 
survey indicates that most respondents give general advice on diet (93%) and 
exercise (94%), but fewer set specific weight loss targets of >5% or >10% 
(Supplemental figure 3). 
 
Pharmacotherapy 
In the absence of any licensed drugs for NASH, most respondents never 
prescribe any specific pharmaco-interventions including vitamin E, insulin 
sensitizers, omega 3 supplements or probiotics. 55% occasionally give advice 
on specific lipid lowering therapy (Supplemental figure 4). 
 
Follow up decision making. 
The survey sought to capture data of factors that influence decisions in 
secondary care to follow up a case of NAFLD, or discharge back to primary 
care. Those factors most strongly favouring secondary care follow-up were: 
NASH with F3/ F4 fibrosis, high risk non-invasive fibrosis test scores, NASH 
with F2 fibrosis, and a child or young person with evidence of NAFLD (figure 
4A). Factors favouring discharge included simple bland steatosis at liver 
biopsy, low risk non-invasive fibrosis tests, current pressures on clinic 
capacity and individual unlikely or unable to lose weight (figure 4B). 
 
DISCUSSION. 
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The publication of clinical practice guidelines for assessment and treatment of 
NAFLD from NICE and EASL- EASD-EASO provides an impetus to improve 
care and service provision for patients with NAFLD. Prior to publication of 
these guidelines, the responses indicate that only a minority of centres had 
local recommendations for NAFLD assessment, particularly district general 
hospitals (3-8%), although only 34% of respondents from specialist liver units 
and 35% from liver transplant centres had local NAFLD guidelines. 
This is the first national cross-sectional survey which attempted to provide 
some context for implementation of the recent NICE guidelines. In light of the 
survey findings we have summarised recommendations to implement 
changes in practice locally that will help move from the position described by 
this survey to improved services for patients with NAFLD (table 2). 
 
The major demand to assess probable NAFLD in secondary care is coming 
from primary care referral to investigate abnormal LFTs. The evidence from 
this survey suggests a likely under recognition of NAFLD in high risk 
individuals, such as those attending diabetes clinics. A significant proportion 
of asymptomatic patients attending type 2 diabetes clinics have undiagnosed 
NAFLD and advanced liver fibrosis 10 and therefore diabetic clinics may be an 
appropriate setting for case-finding.  
 
Simple steps can be implemented into most local referral guidelines and 
pathways to improve standards. These include improved simple clinical 
assessment including alcohol history, measurement of BMI and waist 
circumference in all cases.  
Abnormal LFTs pathways can be streamlined, recognising that NAFLD is  the 
most common reason for referral from primary care for investigation of 
abnormal LFTs7. NAFLD diagnosis can be made in primary care, by exclusion 
of other causes of liver disease. Thus an alcohol history, non-invasive liver 
screen and ultrasound scan to exclude biliary pathology and confirm hepatic 
steatosis are mandatory. Streamlined abnormal LFTs referral pathways 
between primary and secondary care should be developed in all localities to 
prevent unnecessary follow-up appointments. The focus of secondary care 
assessment of NAFLD should be on staging, managing the metabolic 
syndrome and delivering lifestyle interventions. 
 
Following NAFLD diagnosis, non-invasive assessment of liver fibrosis is 
required. NICE advocate the use of ELF testing which could be performed 
exclusively in primary care. However, the survey indicates that only 5% of 
respondents were routinely using ELF. The assessment of fibrosis is generally 
perceived as an added value exercise of a secondary care referral and the 
most widely used tools identified from the survey were transient elastography 
(Fibroscan®), AST / ALT ratio, NFS and Fib-4 scores. All of these modalities 
have an evidence base for having good (>90%) negative predictive values to 
‘rule-out’ advanced fibrosis in those with low scores, but poor positive 
predictive values to ‘rule-in’ NASH with fibrosis in those with higher scores in 
secondary care cohorts 11. 
 
Current NICE and EASL-EASD-EASO guidelines do not specify when liver 
biopsy should be undertaken, but histology is required to diagnose NASH with 
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fibrosis. Most survey respondents indicated that there is a role for liver biopsy, 
which was most strongly favoured when an alternative diagnosis was being 
considered, and in those with high risk non-invasive scores. Liver biopsy has 
an important role in defining eligibility to clinical trials and should be reported 
according to an agreed framework 12 13.  
 
The survey indicates variation in delivery of lifestyle intervention and specific 
management of features of the metabolic syndrome. In many instances 
respondents indicated that secondary care gastroenterologists and 
hepatologists consider this the responsibility for primary care to deliver. We 
advocate that secondary care gastroenterologists and hepatologists 
assessing patients with NAFLD should prescribe a target of 10% weight loss 
over 12 weeks by diet and exercise as first line treatment for NAFLD, and re-
assess response. This can be facilitated in most districts by closer working 
and referral pathways to tier 2 and 3 community weight management 
services, in line with the NICE obesity guidance14. Furthermore, the survey 
highlights variation in ownership of management of features of the metabolic 
syndrome. We advocate a more holistic approach to managing the metabolic 
syndrome by all physicians assessing patients with NAFLD. 
The strengths of this survey are that it is representative of opinion of 
membership of BSG and BASL gastroenterologists and hepatologists in 
secondary care. The study is limited by not including representation from 
primary care, and the data remains qualitative and subjective. It is the 
intention of the UK NAFLD group to repeat the survey, a year after publication 
of NICE guidelines to determine if management of NAFLD patients is 
improving. 
In conclusion, the survey has highlighted priorities for service development to 
adopt recent guidance for NAFLD management, including improved 
recognition of NAFLD in type 2 diabetes, streamlining abnormal LFTs referral 
pathways, defining non-invasive fibrosis assessment, when to perform liver 
biopsy, increasing ownership of managing metabolic syndrome and improving 
access and delivery of lifestyle interventions.  
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Table 1: Responses by centre type for NAFLD guidelines and Liver Fi-
brosis assessment modalities. # Missing responses in completed question-
naires counted as ‘not routine’.  
  All centres DGH Gastro 
 
DGH 
Hepatology 
Interest 
Specialist 
Hepatology 
Liver Transplant 
Units 
Response 
 
Completed 
 
116 (66%) 19 (63%) 34 (68%) 48 (72%) 15 (54%) 
Incomplete 59 (34%) 11 (37%) 16 (32%) 19 (28%) 13 (46%) 
 
 
Local 
NAFLD 
guidelines 
Yes 
 
38 (22%) 1 (3%) 4 (8%) 23 (34%) 10 (35%) 
No# 
 
137 (78%) 29 (97%) 46 (92%) 44 (66%) 18 (65%) 
 
NAFLD Fi-
brosis Score 
Performed in 
all 
48 (41%) 4 (21%) 14 (41%) 22 (46%) 8 (53%) 
Selected 
cases 
29 (25%) 4 (21%) 12 (35%) 10(21%) 3 (20%) 
Not routine# 39 (34%) 11 (58%) 8 (24%) 16 (33%) 4 (27%) 
 
APRI score Performed in 
all 
8 (6%) 0 (0%) 3 (9%) 2 (4%) 3 (20%) 
Selected 
cases 
18 (16%) 1 (5%) 6 (18%) 10 (21%) 1 (7%) 
Not routine# 90 (78%) 18 (95%) 25 (73%) 36 (75%) 11 (73%) 
 
FIB-4 Performed in 
all 
19 (16%) 1 (5%) 3 (9%) 9 (19%) 6 (40%) 
Selected 
cases 
15 (13%) 1 (5%) 2 (6%) 10 (21%) 2 (13%) 
Not routine# 82 (71%) 17 (90%) 29 (85%) 29 (60%) 7 (47%) 
 
Fibroscan Performed in 
all 
58 (50%) 3 (16%) 11 (32%) 34 (71%) 10 (67%) 
Selected 
cases 
46 (40%) 12 (63%) 17 (50%) 12 (25%) 5 (33%) 
Not routine# 12 (10%) 4 (21%) 6 (18%) 2 (4%) 0 (0%) 
 
AST / ALT 
ratio 
Performed in 
all 
62 (53%) 9 (47%) 16 (47%) 28 (58%) 9 (60%) 
Selected 
cases 
24 (21%) 4 (21%) 8 (24%) 10 (21%) 2 (13%) 
Not routine# 30 (26%) 6 (32%) 10 (29%) 10 (21%) 4 (27%) 
 
Liver Biopsy Performed in 
all 
7 (6%) 3 (16%) 0 (0%) 2 (4%) 2 (13%) 
Selected 
cases 
90 (78%) 12 (63%) 22 (65%) 43 (90%) 13 (87%) 
Not routine# 19 (16%) 4 (21%) 12 (35%) 3 (6%) 0 (0%) 
 
ELF test Performed in 
all 
6 (5%) 0 (0%) 1 (3%) 0 (0%) 5 (33%) 
Selected 
cases 
10 (9%) 2 (11%) 1 (3%) 4 (8%) 3 (20%) 
Not routine# 100 (86%) 
 
17 (89%) 32 (94%) 44 (92%) 7 (47%) 
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Table 2 UK NAFLD Group Recommendations for implementation 
Guideline Domain Proposed Actions for 
implementation 
Impact Research priorities 
Identification of 
NAFLD in high risk 
groups 
Screening Primary care 
populations with known type 2 
diabetes for significant NAFLD 
with liver fibrosis as part of the 
existing diabetes QOF. 
Increased NAFLD 
diagnosis in high 
risk patients with 
type 2 diabetes 
Does earlier diagnosis 
of NASH with liver 
fibrosis alter outcomes 
in patients with T2DM? 
Diagnosis Review and streamline referral 
pathways for assessment of 
abnormal LFTs. Perform routine 
diagnostic investigations to 
establish NALFD diagnosis, 
including abdominal ultrasound 
and non-invasive liver screen 
blood tests (hepatitis B & C 
serology), ALT, AST, ferritin, auto-
antibody profile and 
immunoglobulins) in primary care. 
Streamline 
referral pathways 
to decrease 
number of 
hospital outpatient 
appointments. 
Evaluation of 
community based 
programmes for 
NAFLD diagnosis and 
risk stratification 
Staging for 
advanced disease 
Perform a non-invasive test with 
high negative predictive value to 
exclude advanced liver fibrosis in 
primary care, or at point of referral 
for assessment to secondary 
care. Fib 4, NFS, ELF, and 
Transient Elastography all 
suitable depending upon local 
availability. 
Facilitates 
discharge of low 
risk cases, and 
decision to biopsy 
and follow up 
intermediate and 
high risk cases. 
Evaluate the 
diagnostic 
performance and cost 
effectiveness of non-
invasive fibrosis risk 
scores vs ELF vs 
transient elastography 
Liver biopsy Offer liver biopsy to those with 
intermediate and high risk scores 
to diagnose NASH with Fibrosis, 
or re-classify as low risk, and 
reporting using standardised 
criteria. 
Definitive NASH 
diagnosis, access 
to clinical trials 
and those that 
may benefit for 
future licensed 
therapies. 
Evaluation of 
biomarkers and 
imaging as an 
alternative to biopsy 
for NASH diagnosis 
and staging 
Extra-hepatic 
conditions 
Pro-active management of 
features of the metabolic 
syndrome by both primary and 
secondary care. 
Improved 
cardiovascular 
risk reduction 
Specific evidence base 
on which insulin 
sensitizers, lipid 
lowering therapies and 
anti-hypertensive are 
best in NAFLD cases. 
Lifestyle 
intervention 
Set target of 10% weight loss by 
diet and exercise as first line 
treatment for all cases of NAFLD 
 
Increase access to tier 2 and 3 
weight management services to 
deliver weight loss as first line 
NAFLD treatment 
Improved efficacy 
of lifestyle 
intervention to 
treat NASH. 
 
Define lifestyle 
non-responders 
who may benefit 
from trials and 
future therapies 
What factors influence 
response /non-
response to lifestyle 
intervention? 
Trials Individuals with NASH and ≥F2 
fibrosis should be offered access 
to clinical trials, and long term 
follow up in secondary care to 
assess fibrosis progression  
Evidence base for 
NASH specific 
therapies 
Which interventions 
are most efficacious, in 
which populations? 
Factors that determine 
response and non-
response? 
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UK NAFLD survey data - estimated number of referrals to gastroenterology and hepatology with abnormal 
liver function tests.(Number of respondents)  
Figure 1  
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Modalities performed to assess for liver fibrosis (% of respondents)  
Figure 2  
155x94mm (150 x 150 DPI)  
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Factors influencing use of liver biopsy in NAFLD assessment.  
Figure 3  
270x152mm (120 x 120 DPI)  
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Figure 4A (top panel) factors favouring follow-up in secondary care. 4B (bottom panel) factors favouring 
discharge from secondary care.  
Figure 4  
196x161mm (150 x 150 DPI)  
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Appendix 1: Contributing centres: 
 
We would like to thank respondents contributing to the survey from the 
following centres: 
Aberdeen Royal Infirmary 
Addenbrookes, Cambridge 
Aintree University Hospital 
Aneurin Bevan University Health Board 
Arrowe Park Hospital 
Ayreshire Hospital 
Barnet Hospital 
Barts Health NHS Trust 
Birmingham Children’s Hospital 
Birmingham Heartlands Hospital 
Borders General Hospital, Melrose 
Brighton & Sussex University Hospitals 
Broomfield Hospital, Mid Essex 
Chesterfield Royal Hospital 
Coventry Hospital 
Ealing Hospital 
East Kent Hospital 
East Surrey Hospital 
Fife NHS Trust 
Gateshead NHS Foundation Trust 
Glasgow Royal Infirmary 
Gloucestershire Royal Hospital 
Guys and St Thomas' Hospital 
Hull and East Yorkshire NHS Trust 
Kettering General Hospital 
Kings College Hospital 
Leeds 
Lewisham & Greenwich NHS Trust 
Lincoln County Hospital 
Lister, Stevenage 
London North West healthcare NHS Trust 
Newcastle upon Tyne Hospitals NHS Foundation Trust 
NHS Grampian 
NHS Highland 
NHS Lothian 
NHS Tayside, Dundee 
Norfolk & Norwich NHS Trust 
North Bristol NHS Trust 
North Cumbria University Hospitals 
North Middlesex Hospital 
North Tees & Hartlepool 
Nottingham University Hospitals 
Oxford, John Radcliffe 
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Pennine Acute Hospitals NHS Trust 
Plymouth Hospitals NHS Trust 
Poole Hospital 
Portsmouth Hospital 
Prince Charles Hospital, Cwm Taf, HB 
Queen Elizabeth University Hospital, Glasgow 
Queen Elizabeth Hospital Birmingham 
Royal Alexandra Hospital, Paisley 
Royal Berkshire Hospital 
Royal Bolton Hospital 
Royal Bournemouth Hospital 
Royal Derby Hospital 
Royal Devon & Exeter Hospital 
Royal Free Hospital 
Royal Infirmary of Edinburgh 
Royal Liverpool Hospital 
Royal London Hospital 
Royal United Hospital, B th 
Royal Victoria Hospital, Belfast 
Salisbury NHS Foundation Trust 
Shaheed Ziaur Rahman Medical College Hospital 
Sheffield 
Solihull Hospital 
South Tees NHS Foundation Trust 
South Tyneside Hospital 
St John’s Hospital, Livingston 
St Marys / Imperial Healthcare 
Taunton Hospital 
Torbay 
Toronto General hospital 
UHNM Royal Stoke Hospital 
University Hospital Bristol 
University Hospital of Wales 
University Hospitals Leicester 
Western Sussex Hospitals NHS Foundation Trust 
(Worthing & Chichester) 
Wirral University Hospital 
Wishaw General Hospital, Lanarkshire 
Withybush Hospital, Hyel Dda HB 
Worcester Hospital 
Wrightinton, Wigan and Leigh NHS Foundation Trust 
Wye Valley 
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Appendix 2: Full list of survey questions 
 
Q1. Do you have local hospital guidelines for assessment of NAFLD? 
  
 
Please describe your centre according to one of the following 
categories: 
 
Answer Choices– Responses  
 
District General Hospital, liver services 
provided by general gastroenterology 
30  
 
District General Hospital, liver services 
delivered by gastroenterologists with an 
interest in hepatology 
50  
 
A specialist centre providing designated 
hepatology services 
67  
 
A liver transplant unit 
28  
 
We have local NAFLD guidelines 
38  
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Q2 How many referrals does your unit receive per year from for 
investigation of abnormal LFTs, from Primary Care; Diabetes / 
metabolic; Rheumatology / Dermatology? 
 
  
 
From Primary care– From diabetes / metabolic 
medicine services– 
From rheumatology / 
dermatology– 
 
<50 
 
5 (5%) 
 
63(64%) 
 
64 (65%) 
 
51-100 
 
14 (13%) 
 
29 (29%) 
 
26 (27%) 
 
101-200 
 
23 (21%) 
 
5 (5%0 
 
6 (6%) 
 
201-300 
 
19 (17%) 
 
0 
 
0 
 
>300 
 
49 (44%) 
 
2 (2%) 
 
2 (2%) 
Total 
Responses 
110 99 98 
 
don't know 
 
35 
 
39 
 
40 
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Q3 When triaging a referral with abnormal LFTs in your unit with 
suspected NAFLD, which of the following tests are performed routinely 
by the referring primary care team or receiving secondary care team? 
 
 
 
Routinely 
performed by 
GP before first 
hospital visit– 
Performed routinely 
by hospital team at 
or following initial 
visit in all patients– 
Performed in 
selected cases– 
Not routinely 
performed in our 
unit– 
Total 
Respondents– 
Missing / 
incomplete 
responses 
 
Body Mass Index 
25.86% 
30 
82.76% 
96 
7.76% 
9 
1.72% 
2 
 
116 
0 
 
Alcohol history 
55.17% 
64 
79.31% 
92 
1.72% 
2 
0.86% 
1 
 
116 
0 
 
Waist circumference 
1.16% 
1 
17.44% 
15 
29.07% 
25 
55.81% 
48 
 
86 
30 
 
GGT 
42.59% 
46 
58.33% 
63 
9.26% 
10 
15.74% 
17 
 
108 
8 
 
AST 
33.63% 
38 
71.68% 
81 
8.85% 
10 
4.42% 
5 
 
113 
3 
 
ALT 
70.43% 
81 
69.57% 
80 
0.00% 
0 
0.87% 
1 
 
115 
1 
 
Ferritin 
22.61% 
26 
87.83% 
101 
1.74% 
2 
1.74% 
2 
 
115 
1 
 
Hepatitis B and C 
serology 
32.76% 
38 
86.21% 
100 
3.45% 
4 
0.00% 
0 
 
116 
0 
 
Liver auto-antibody 
screen and 
immunoglobulins 
19.13% 
22 
91.30% 
105 
1.74% 
2 
0.00% 
0 
 
115 
1 
 
Liver and biliary tree 
ultrasound scan 
37.07% 
43 
81.03% 
94 
2.59% 
3 
0.00% 
0 
 
116 
0 
 
Fibroscan 
0.00% 
0 
50.88% 
58 
40.35% 
46 
8.77% 
10 
 
114 
2 
 
ELF test or other 
serum fibrosis 
marker 
2.08% 
2 
6.25% 
6 
10.42% 
10 
83.33% 
80 
 
96 
20 
 
Fatty Liver Index 
(FLI) score 
1.06% 
1 
5.32% 
5 
6.38% 
6 
89.36% 
84 
 
94 
22 
 
NAFLD Fibrosis 
score 
6.60% 
7 
45.28% 
48 
27.36% 
29 
27.36% 
29 
 
106 
10 
 
APRI score 
0.00% 
0 
8.79% 
8 
19.78% 
18 
71.43% 
65 
 
91 
25 
 
FIB-4 score 
3.13% 
3 
19.79% 
19 
15.63% 
15 
63.54% 
61 
 
95 
21 
 
AST / ALT ratio 
7.84% 
8 
57.94% 
62 
22.43% 
24 
19.63% 
21 
 
107 
9 
 
Cytokeratin 18 
0.00% 
0 
3.16% 
3 
4.21% 
4 
94.74% 
90 
 
95 
21 
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Routinely 
performed by 
GP before first 
hospital visit– 
Performed routinely 
by hospital team at 
or following initial 
visit in all patients– 
Performed in 
selected cases– 
Not routinely 
performed in our 
unit– 
Total 
Respondents– 
Missing / 
incomplete 
responses 
(M30 and / or M65) 
 
Liver biopsy 
0.00% 
0 
6.54% 
7 
84.11% 
90 
9.35% 
10 
 
107 
9 
 
random glucose 
24.27% 
25 
67.96% 
70 
11.65% 
12 
7.77% 
8 
 
103 
13 
 
HbA1C 
20.00% 
21 
60.95% 
64 
22.86% 
24 
6.67% 
7 
 
105 
11 
 
non-fasting lipid 
profile 
17.35% 
17 
66.33% 
65 
11.22% 
11 
13.27% 
13 
 
98 
18 
 
fasting glucose 
11.96% 
11 
28.26% 
26 
51.09% 
47 
14.13% 
13 
 
92 
24 
 
fasting lipid profile 
15.15% 
15 
32.32% 
32 
48.48% 
48 
13.13% 
13 
 
99 
17 
 
fasting insulin 
0.00% 
0 
2.17% 
2 
25.00% 
23 
73.91% 
68 
 
92 
24 
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Q4 In respect to liver biopsy in cases of NAFLD 
  
 
Strongly 
agree– 
Agree– Neither agree nor 
disagree– 
Disagree– Strongly 
disagree– 
 
is indicated 
with 
intermediate-
risk non-
invasive risk 
scores (e.g. 
ELF, NAFLD 
Fibrosis 
score, FIB4 
score, AST / 
ALT ratio) 
8.93% 
10 
38.39% 
43 
28.57% 
32 
21.43% 
24 
2.68% 
3 
 
is indicated 
with high-
risk non-
invasive risk 
scores (e.g. 
ELF, NAFLD 
Fibrosis 
score, FIB4 
score, 
AST/ALT 
ratio) 
21.24% 
24 
31.86% 
36 
17.70% 
20 
26.55% 
30 
2.65% 
3 
 
is indicated 
when other 
non-invasive 
tests are 
unreliable 
(e.g. 
Fibroscan 
with IQR 
>30%) 
16.96% 
19 
54.46% 
61 
23.21% 
26 
4.46% 
5 
0.89% 
1 
 
is indicated 
with >2 
metabolic 
syndrome 
features 
0.89% 
1 
7.14% 
8 
43.75% 
49 
45.54% 
51 
2.68% 
3 
 
is indicated 
with >3 
metabolic 
syndrome 
features 
2.70% 
3 
13.51% 
15 
37.84% 
42 
41.44% 
46 
4.50% 
5 
 
is useful to 
exclude 
an alternative 
diagnosis e.g 
auto-immune 
liver disease 
25.66% 
29 
58.41% 
66 
12.39% 
14 
3.54% 
4 
0.00% 
0 
 
to required to 
make a 
diagnosis of 
NASH 
18.02% 
20 
33.33% 
37 
13.51% 
15 
30.63% 
34 
4.50% 
5 
 
is poorly 
3.57% 
4 
20.54% 
23 
30.36% 
34 
39.29% 
44 
6.25% 
7 
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Strongly 
agree– 
Agree– Neither agree nor 
disagree– 
Disagree– Strongly 
disagree– 
tolerated by 
patients 
 
does not 
alter 
management 
of NAFLD 
4.46% 
5 
17.86% 
20 
25.00% 
28 
45.54% 
51 
7.14% 
8 
 
is helpful to 
understand 
disease 
progression 
8.93% 
10 
53.57% 
60 
25.00% 
28 
11.61% 
13 
0.89% 
1 
 
 
  
Page 27 of 33
https://mc.manuscriptcentral.com/fg
Frontline Gastroenterology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Q5. What lifestyle interventions and support do you regularly access for 
your patients with NAFLD? (tick all that apply) 
 
Answer Choices– Responses– 
 
a multidisciplinary clinic with dieticans and physiotherapy 
20.91% 
23 
 
direct access to tier 2 weight mamangement (BMI<35) 
26.36% 
29 
 
direct access to tier 3 weight management services (BMI>35) 
22.73% 
25 
 
direct access to tier 4 weight management services (BMI>40) including 
assessment for bariatric surgery 
26.36% 
29 
 
access to weight management services by referral from GP 
56.36% 
62 
 
no additional lifestyle intervention support available 
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Q6. What advice do you give NAFLD patients about alcohol 
consumption? 
 
Answer Choices– Responses– 
 
To always remain completely abstinent from alcohol 
20.18% 
22 
 
To drink < 14 units per week in those without advanced fibrosis 
70.64% 
77 
 
Explain that alcohol is calorific and should be moderated to help reduce weight 
63.30% 
69 
 
There is insufficient evidence to make a recommendation 
2.75% 
3 
 
I do not routinely advise on safe alcohol consumption 
1.83% 
2 
Total Respondents: 109   
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Q7. With respect to interventions in cases of NAFLD / NASH do you 
recommend and / or prescribe the following: 
 
 
 
I usually / 
routinely do 
this– 
I do this occasionally 
in selected cases– 
I never do 
this– 
 
dietary advice 
96.40% 
107 
3.60% 
4 
0.00% 
0 
 
exercise advice 
94.59% 
105 
5.41% 
6 
0.00% 
0 
 
weight loss 
target of >5% 
47.87% 
45 
30.85% 
29 
21.28% 
20 
 
weight loss 
target of >10% 
53.40% 
55 
35.92% 
37 
10.68% 
11 
 
vitamin E 
1.83% 
2 
23.85% 
26 
74.31% 
81 
 
specific insulin 
sensitisers e.g. 
pioglitazone, 
liraglutide 
1.83% 
2 
46.79% 
51 
51.38% 
56 
 
omega-3 
supplements 
0.00% 
0 
10.00% 
11 
90.00% 
99 
 
specific lipid 
lowering 
therapies 
13.51% 
15 
54.95% 
61 
31.53% 
35 
 
probiotics 
0.00% 
0 
5.50% 
6 
94.50% 
103 
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Q8. Who manages features of metabolic syndrome in the patients you 
see with NAFLD? 
 
  
 
Specifically 
managed by 
you– 
you provide advice to 
GP or other healthcare 
provider to manage 
this– 
you 
request GP to 
manage this– 
you 
don't advise 
on this– 
your centre has a 
multidisciplinary 
metabolic service to 
manage this– 
 
type 2 diabetes 
e.g. advice on 
specific 
treatments and 
glycaemic 
control 
e.g.HbA1c 
0.91% 
1 
40.00% 
44 
47.27% 
52 
0.91% 
1 
10.91% 
12 
 
obesity 
4.59% 
5 
46.79% 
51 
31.19% 
34 
0.92% 
1 
16.51% 
18 
 
hypertension 
0.91% 
1 
24.55% 
27 
63.64% 
70 
2.73% 
3 
8.18% 
9 
 
hyperlipidaemia 
1.82% 
2 
33.64% 
37 
51.82% 
57 
1.82% 
2 
10.91% 
12 
 
cardiovascular 
risk profile e.g. 
QRISK2 score 
& statin 
prescribing 
1.83% 
2 
29.36% 
32 
54.13% 
59 
7.34% 
8 
7.34% 
8 
 
obstructive 
sleep apnoea 
0.92% 
1 
43.12% 
47 
23.85% 
26 
20.18% 
22 
11.93% 
13 
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Q9. Which of the following imaging modalities are available in your unit? 
 
– 
Routinely available 
and used– 
Available, but used for selected cases 
only including research studies– 
Unavailable at 
our unit– 
Don't know– 
 
Transient 
Elastography 
(Fibroscan) 
M Probe 
70.37% 
76 
6.48% 
7 
20.37% 
22 
2.78% 
3 
 
Transient 
Elastography 
(Fibroscan) 
XL Probe 
63.89% 
69 
6.48% 
7 
24.07% 
26 
5.56% 
6 
 
Controlled 
attenuation 
parameter 
(CAP) 
28.57% 
30 
4.76% 
5 
56.19% 
59 
10.48% 
11 
 
Acoustic 
radiation 
force 
impulse 
(ARFI) 
5.61% 
6 
12.15% 
13 
71.03% 
76 
11.21% 
12 
 
MRI 
elastography 
0.94% 
1 
15.09% 
16 
73.58% 
78 
10.38% 
11 
 
Magnetic 
Resonance 
Imaging 
estimated 
proton 
density fat 
fraction 
(MRI-PDFF) 
0.93% 
1 
14.95% 
16 
68.22% 
73 
15.89% 
17 
 
Magnetic 
Resonance 
Spectroscopy 
– proton 
density fat 
fraction 
(MRS-
PDFF) 
0.93% 
1 
14.81% 
16 
68.52% 
74 
15.74% 
17 
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Q10. Please describe to what extent the following factors influence your 
decision to follow up or discharge a patient with NAFLD from your 
clinic. 
 
 
Strongly 
favours 
ongoing follow 
up– 
Favours 
ongoing 
follow up– 
Neutral– Favours 
discharge to 
primary care– 
Strongly 
favours 
discharge to 
primary care– 
 
A child or young person 
with evidence of NAFLD 
22.43% 
24 
45.79% 
49 
16.82% 
18 
14.95% 
16 
0.00% 
0 
 
The presence of Type 2 
diabetes 
7.55% 
8 
34.91% 
37 
47.17% 
50 
10.38% 
11 
0.00% 
0 
 
South Asian ethnicity 
1.89% 
2 
31.13% 
33 
57.55% 
61 
9.43% 
10 
0.00% 
0 
 
Low risk non-
invasive investigations for 
advanced fibrosis 
1.85% 
2 
2.78% 
3 
9.26% 
10 
61.11% 
66 
25.00% 
27 
 
Intermediate risk non-
invasive investigations for 
advanced fibrosis 
7.55% 
8 
52.83% 
56 
25.47% 
27 
14.15% 
15 
0.00% 
0 
 
High risk non-invasive 
investigations for 
advanced fibrosis 
51.85% 
56 
40.74% 
44 
2.78% 
3 
3.70% 
4 
0.93% 
1 
 
Current pressures on 
clinic capacity 
2.83% 
3 
7.55% 
8 
51.89% 
55 
33.02% 
35 
4.72% 
5 
 
Individual is unlikely or 
unable to lose weight 
0.00% 
0 
18.87% 
20 
54.72% 
58 
24.53% 
26 
1.89% 
2 
 
Liver biopsy showing 
simple / bland steatosis 
without inflammation, 
ballooning or fibrosis 
0.93% 
1 
8.33% 
9 
9.26% 
10 
51.85% 
56 
29.63% 
32 
 
Liver biopsy showing 
NASH (NAS score 
>4) with early F1 fibrosis 
13.33% 
14 
43.81% 
46 
17.14% 
18 
25.71% 
27 
0.00% 
0 
 
Liver biopsy showing 
NASH with moderate F2 
fibrosis 
38.68% 
41 
40.57% 
43 
8.49% 
9 
12.26% 
13 
0.00% 
0 
 
Liver biopsy showing 
NASH with advanced 
F3/F4 fibrosis 
73.15% 
79 
25.93% 
28 
0.93% 
1 
0.00% 
0 
0.00% 
0 
 
Lack of robust recall 
guidelines for primary 
care 
5.56% 
6 
31.48% 
34 
58.33% 
63 
2.78% 
3 
1.85% 
2 
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